Rezum Water Vapor Therapy
TMBS E269: Dr. Rahul Mehan – Rezūm™ Water Vapor Therapy
At last an answer for men over 60 that suffer prostatic hyperplasia (BPH) enlarged prostate conditions. Dr. Rahul Mehan is Mark’s guest for this episode sharing this incredible non-surgical water vapor therapy called Rezūm™ Water Vapor Therapy.
Overview of the #Rezum Water Vapor Therapy
Dr. Rahul Mehan
https://www.iheart.com/podcast/53-the-mark-bishop-show-82657128/episode/tmbs-e269-dr-rahul-mehan–103504451/ – October 19, 2022 • 10 mins
Rezūm™ Water Vapor Therapy is a non-surgical treatment for men 50 years or older that can be performed in a doctor’s office. Rezūm Therapy uses the energy stored in water vapor to reduce the size of the prostate, providing lasting BPH symptom relief while preserving sexual and urinary function.[v] Patients who receive Rezūm Therapy can typically resume normal activities within a few days after treatment and most patients see symptom improvement within two weeks.5
For more information please visit: www.rezum.com
[i] Interviews represent a collaborative education activity between Dr. Rahul Mehan and Boston Scientific Corporation. Physicians are not compensated for his time.
[ii] Harvard Health. The growing problem of an enlarged prostate gland. Available at: https://www.health.harvard.edu/mens-health/the-growing-problem-of-an-enlarged-prostate-gland. Accessed July 2022.
[iii] Mayo Clinic. Benign prostatic hyperplasia. Available at: https://www.mayoclinic.org/diseases-conditions/benign-prostatic-hyperplasia/symptoms-causes/syc-20370087. Accessed July 2022.
[iv] Gupta N, Rogers T, Holland B, et al. Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J Urol. 2018 Aug;200(2):405-413.
[v] McVary KT, Gittelman MC, Goldberg KA, et al. Final 5‐year outcomes of the multicenter randomized sham‐controlled trial of Rezūm water vapor thermal therapy for treatment of moderate‐to‐severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021 Sep;206(3):715‐24.